Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Common Equity (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Common Equity for 16 consecutive years, with $137.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Common Equity rose 39.54% to $137.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $137.4 million, a 39.54% increase, with the full-year FY2024 number at $63.3 million, up 353.93% from a year prior.
  • Common Equity was $137.4 million for Q3 2025 at Gyre Therapeutics, up from $129.4 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $137.4 million in Q3 2025 to a low of $13.9 million in Q4 2023.
  • A 5-year average of $78.2 million and a median of $79.1 million in 2022 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: plummeted 80.68% in 2023, then surged 353.93% in 2024.
  • Gyre Therapeutics' Common Equity stood at $59.5 million in 2021, then rose by 21.44% to $72.2 million in 2022, then tumbled by 80.68% to $13.9 million in 2023, then soared by 353.93% to $63.3 million in 2024, then skyrocketed by 117.02% to $137.4 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Common Equity are $137.4 million (Q3 2025), $129.4 million (Q2 2025), and $104.3 million (Q1 2025).